Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Non-Current Debt (2020)

Caribou Biosciences has reported Non-Current Debt over the past 1 years, most recently at $924000.0 for Q4 2020.

  • Quarterly Non-Current Debt changed N/A to $924000.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $924000.0 through Dec 2020, changed N/A year-over-year, with the annual reading at $924000.0 for FY2020, N/A changed from the prior year.
  • Non-Current Debt was $924000.0 for Q4 2020 at Caribou Biosciences.
  • Over five years, Non-Current Debt peaked at $924000.0 in Q4 2020 and troughed at $924000.0 in Q4 2020.